Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,215
  • Shares Outstanding, K 4,307
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,080 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.91
  • Most Recent Earnings $-0.87 on 11/14/24
  • Next Earnings Date 03/06/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6251 +58.37%
on 12/11/24
3.3900 -70.80%
on 12/19/24
+0.2500 (+33.78%)
since 12/10/24
3-Month
0.5933 +66.86%
on 12/06/24
3.3900 -70.80%
on 12/19/24
-0.1500 (-13.16%)
since 10/10/24
52-Week
0.5933 +66.86%
on 12/06/24
11.5800 -91.45%
on 01/11/24
-10.2100 (-91.16%)
since 01/10/24

Most Recent Stories

More News
Bio-Path Holdings Provides 2025 Clinical and Operational Update

BPTH : 0.9702 (-0.86%)
Is This Penny Stock a Buy After a 180% Rally?

Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.

BPTH : 0.9702 (-0.86%)
Bio-Path Holdings, Inc. Reports Promising Preclinical Results for BP1001-A as a Potential Treatment for Obesity and Type 2 Diabetes

Bio-Path Holdings reports BP1001-A shows promise for treating obesity and Type 2 diabetes by enhancing insulin sensitivity.Quiver AI SummaryBio-Path Holdings, Inc. announced promising preclinical results...

BPTH : 0.9702 (-0.86%)
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode

The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.

VXF : 188.85 (-1.73%)
BPTH : 0.9702 (-0.86%)
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

BPTH : 0.9702 (-0.86%)
Bio-Path Holdings, Inc. Shift Focus to BP1001-A Development for Type 2 Diabetes and Discontinue BP1002 Enrollment Due to Challenges

Bio-Path Holdings reallocates resources to BP1001-A for obesity treatment, discontinuing BP1002 lymphoma study due to enrollment challenges.Quiver AI SummaryBio-Path Holdings, Inc. has announced plans...

BPTH : 0.9702 (-0.86%)
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

BPTH : 0.9702 (-0.86%)
Bio-Path Holdings, Inc. Expands DNAbilize® Technology to Obesity Treatment, Reveals Third Quarter Financial Results

Bio-Path Holdings reports Q3 2024 results, initiating obesity program, advancing oncology trials, and closing a $4M private placement.Quiver AI SummaryBio-Path Holdings, Inc. has expanded its DNAbilize®...

BPTH : 0.9702 (-0.86%)
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 0.9702 (-0.86%)
Bio-Path Holdings Reports Third Quarter 2024 Financial Results

BPTH : 0.9702 (-0.86%)

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

3rd Resistance Point 1.2611
2nd Resistance Point 1.1905
1st Resistance Point 1.0846
Last Price 0.9702
1st Support Level 0.9081
2nd Support Level 0.8375
3rd Support Level 0.7316

See More

52-Week High 11.5800
Fibonacci 61.8% 7.3831
Fibonacci 50% 6.0866
Fibonacci 38.2% 4.7902
Last Price 0.9702
52-Week Low 0.5933

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar